IP Library Granted Patent US 7,404,489
Granted Patent B1
US 7,404,489 · App. 10/814,399 · Granted Jul 29, 2008

Cyanocobalamin low viscosity aqueous formulations for intranasal delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,404,489
App. No.
10/814,399
Granted
Jul 29, 2008
Kind
B1
Abstract

A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

Claims (21)

1. A pharmaceutical kit for nasal drug delivery comprising:

an aqueous solution of cyanocobalamin and excipients in a container and;

a droplet-generating actuator attached to said container and fluidly connected to the cyanocobalamin solution in the container; wherein said actuator produces a spray of the cyanocobalamin solution through a tip of the actuator when said actuator is engaged, wherein said spray of cyanocobalamin solution has a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0 cm from the actuator tip.

2. The kit of claim 1 wherein said spray comprises droplets wherein less than 5% of said droplets are less than 10 μm in size.

3. The kit of claim 1 wherein the aqueous solution of cyanocobalamin has a viscosity of less than 1000 cPs, with the proviso that mercury and mercury containing compounds are not present in the solution.

4. The kit of claim 3 wherein the spray is comprised of droplets of the cyanocobalamin solution wherein less than 5% of the droplets are less than 10 μm in size.

5. The kit of claim 3 wherein the spray has a spray pattern major axis and minor axis of between 25 and 40 mm each.

6. The kit of claim 3 wherein the solution of cyanocobalamin is further comprised of citric acid and sodium citrate wherein the solution has a pH of from about 4-6.

7. The kit of claim 6 wherein the pH of the solution is about 5.

8. The kit of claim 3 wherein cyanocobalamin is present in solution at a concentration of between 0.5-1% by weight.

9. The kit of claim 8 wherein the concentration of cyanocobalamin in solution is about—0.5%.

10. The kit of claim 6 wherein the citric acid is present in solution at a concentration of about 0.12%, and the sodium citrate is present in solution at a concentration of about 0.32%, in water.

11. The kit of claim 3 wherein the cyanocobalamin spray is comprised of droplets of the cyanocobalamin solution wherein 50% of the droplets are 26.9 μm or less in size.

12. The kit of claim 3 wherein the cyanocobalamin spray is comprised of droplets of the cyanocobalamin solution, wherein 90% of the droplets are 55.3 μm or less in size.

13. The kit of claim 3 wherein the cyanocobalamin spray produces droplets of the solution, and wherein 10% of the droplets are 12.5 μm or less in size.

14. A kit for administering intranasally a cyanocobalamin solution comprised of a container, a solution of cyanocobalamin in the container, and an actuator attached to said container, wherein a spray of cyanocobalamin solution is expelled through a tip of said actuator when said actuator is engaged wherein said aqueous solution of cyanocobalamin is comprised of cyanocobalamin at a concentration of about 0.5% of total weight of solution, citric acid at a concentration of about 0.12%, sodium citrate at a concentration of about 0.32%, glycerin at a concentration of about 2.23%, benzalkonium chloride at concentration of about 0.02% and water wherein said solution of cyanocobalamin is suitable for intranasal administration, and has a viscosity less than about 1000 cPs, with the proviso that the solution of cyanocobalamin contains no mercury or mercury-containing compounds, and wherein the spray has a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0 cm from the actuator tip.

15. The kit of claim 14 wherein the cyanocobalamin spray is comprised of droplets of the cyanocobalamin solution, wherein less than 5% of the droplets of the cyanocobalamin spray are less than 10 μm in size.

16. The kit of claim 14 wherein the cyanocobalamin spray is comprised of droplets of the cyanocobalamin solution, and wherein 50% of the droplets of the cyanocobalamin spray are 26.9 μm or less in size.

17. The kit of claim 14 wherein the cyanocobalamin spray produces droplets of the solution, and wherein 90% of the droplets are 55.3 μm or less in size.

18. The kit of claim 14 wherein the cyanocobalamin spray produces droplets of the solution, and wherein 10% of the droplets are 12.5 μm or less in size.

19. The kit of claim 14 wherein the spray has a spray pattern major axis of about 35.3 mm and a minor axis of about 30.8 mm.

Assignments (20)
SECURITY INTEREST Recorded Jul 22, 2024
From: ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 068469/0001 →
SECURITY INTEREST Recorded Jul 19, 2024
From: ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: GOLDMAN SACHS BANK USA
Reel/Frame 068461/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2024
From: ENDO USA, INC.
To: ENDO OPERATIONS LIMITED
Reel/Frame 067245/0492 →
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067240/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0491 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2024
From: ENDO PHARMACEUTICALS INC.
To: ENDO USA, INC.
Reel/Frame 067203/0398 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 17, 2021
From: ASTORA WOMEN'S HEALTH LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS INC.; PAR PHARMACEUTICAL, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057538/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2017
From: PAR PHARMACEUTICAL, INC.; ENDO PAR INNOVATION COMPANY, LLC
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 043118/0747 →
SECURITY INTEREST Recorded Jun 8, 2017
From: PAR PHARMACEUTICAL, INC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 042743/0216 →
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: PAR PHARMACEUTICAL, INC.; ENDO GENERICS HOLDINGS, INC.; INNOTEQ, INC.
Reel/Frame 042171/0036 →
RELEASE OF SECURITY INTEREST Recorded Sep 30, 2015
From: BANK OF AMERICA, N.A.
To: PAR PHARMACEUTICAL, INC.; INNOTEQ, INC.; PAR PHARMACEUTICAL COMPANIES, INC.
Reel/Frame 036695/0782 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 25, 2015
From: PAR PHARMACEUTICAL, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 036687/0821 →
SECURITY AGREEMENT Recorded Oct 1, 2012
From: PAR PHARMACEUTICAL COMPANIES, INC.; PAR PHARMACEUTICAL, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 029061/0252 →
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2009
From: FULL CIRCLE PARTNERS, LP; FCC, LLC
To: QOL MEDICAL, LLC
Reel/Frame 022482/0149 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2009
From: QOL MEDICAL, LLC
To: PAR PHARMACEUTICAL, INC.
Reel/Frame 022482/0155 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SCHEDULE A PREVIOUSLY RECORDED ON REEL 019580 FRAME 0549. ASSIGNOR(S) HEREBY CONFIRMS THE SCHEDULE 1. Recorded Feb 29, 2008
From: NASTECH PHARMACEUTICAL COMPANY, INC.
To: QOL MEDICAL, LLC
Reel/Frame 020617/0687 →
SECURITY AGREEMENT Recorded Dec 6, 2007
From: QOL MEDICAL, LLC
To: FCC, LLC D/B/A FIRST CAPITAL
Reel/Frame 020206/0015 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2007
From: NASTECH PHARMACEUTICAL COMPANY INC.
To: QOL MEDICAL, LLC
Reel/Frame 019580/0549 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ZIP CODE IN THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 014814 FRAME 0502. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ASSIGNEES ADDRESS (ZIP CODE SHOULD BE 98021-8906)IN PREVIOUSLY RECORDED ASSIGNMENT. Recorded Aug 9, 2004
From: QUAY, STEVEN C.; GO, ZENAIDA O.; APRILE, PETER C; SILENO, ANTONY P.
To: NASTECH PHARMACEUTICAL COMPANY INC.
Reel/Frame 014965/0801 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2004
From: QUAY, STEVEN C.; APRILE, PETER C.; GO, ZENAIDA O.; SILENO, ANTHONY P.
To: NASTECH PHARMACEUTICAL COMPANY INC.
Reel/Frame 014814/0502 →